Cancer Fun at Chemo with Saranne

Today on Beating Cancer Daily, Saranne, founder of the ComedyCures Foundation and a Stage IV cancer survivor for over 30 years, shares fresh and creative ways to infuse fun and positivity into the chemotherapy experience. Drawing from her signature chemo comedy parties and inspired by the joyful outlook of fellow survivors like Leah, Saranne encourages listeners to create tangible lists of things that could brighten up their chemo sessions. She explores the transformative effects of giving, building camaraderie with chemo buddies, engaging with playful gifts or small acts of kindness, and emphasizes the importance of setting mental boundaries to keep chemo from overshadowing daily life. Saranne also weaves in insights from behavioral science, sharing simple psychological tools and practical strategies to make the chemotherapy process less daunting and more enjoyable, revealing how laughter, connection, and intentional joy can become powerful medicine.Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 Beating Cancer Daily is listened to in over 130 countries on 7 continents and has over 365 original daily episodes hosted by Stage IV survivor Saranne Rothberg!   To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne 

There are no comments yet.

Please log in to write the first comment.